A XENOTHERAPY PLATFORM WITH EMBEDDED TECHNOLOGY
THAT RENOVATES IMMUNOLOGICAL TREATMENTS

Innovative immunotherapy

XENOTHERA’s platform for creating of hyperimmune polyclonal sera is based on the following proprietary processes:

Define the proper animal and its genetic background for engineering
Choose and optimize the immunogen
Turn the animal’s immune response for an optimized therapeutic efficiency
Purify the antibodies
Lead a translational development program
Product and commercialize

Therapeutic domains:

Immunology
Infectious diseases 
Anti-toxins and venoms
Oncology
Others

Seasoned entrepreneurs with demonstrated past successes

Executive

ODILE DUVAUX

CEO

M.D., Ph. D., formerly main partner in a consultant firm specialized in strategy: DMJ Consultants

Scientific advisor

JEAN-PAUL SOULILLOU

CSO

Emeritus Professor of Medicine, worldwide renowned immunologist. 2016 winner Medawar Prize

Scientific advisor

EMANUELE COZZI

Chairman of the Scientific Advisory Board

MD, Professor of Immunology at the University of Padua, former chairman of the International Xenotransplantation Association

Scientific advisor

JEAN-MARIE BACH

DMV, Ph.D., Professor at Oniris, Veterinary school of Nantes

Scientific advisor

CESARE GALLI

Genetic engineering

D.M.V., Ph.D., founder of the company Avantea (Cremona, Italy), worldwide renowned animal genetic engineer

Scientific advisor

MARC BOUILLET

M.D., former partner/CEO in several pharmaceutical companies and patient associations

An agile company with a fast-paced development

XENOTHERA is a biotechnology start-up company at the top of innovation, which creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases.

Our technological platform is built on a double expertise of animal genetics and mastery of immunological processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Our antibodies are engineered to display specific properties with reduced adverse effects and enhanced biological properties.

XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale.

Latest News

XENOTHERA sponsors the realization of a fresco for the hospital by transplanted patients

Nantes, november 2017 The fresco, more than 8 meters long, has been set up in the hall of the Institute of Transplantation of Nantes, France, where all patients, doctors and[…]

Read more

XENOTHERA nominated for the Ernst&Young Entrepreneur Award

Nantes, September 2017 We have been selected for the 2017 entrepreneur awards of Ernst & Young…

Read more

Distinction: Jean-Paul SOULILLOU awarded for its international exceptional career and contribution in transplantation

August 25th, 2016 XENOTHERA, a young start-up from Nantes, is honored to announce that one of the founders of the company, Prof. Jean-Paul SOULILLOU, Emeritus at the Medicine Faculty of[…]

Read more

Press Release: Start-up XENOTHERA closes a new capital increase above 2 million euros

June 10th, 2016 XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more than 2 million euros

Read more

Xenothera is built on a worldwide network of scientific partners

Related scientific papers

Anti-Gal and anti-Neu5GC responses in non-immunosuppressed patients following treatment with anti-thymocyte globulin

Salama et al, ESOT 2017, Oral presentation
Transplant International, volume 30, Supplement 2

LINK

Neu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs.

Salama et al, Diabetes, 2017

LINK

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs

Reynard et al, PLoS One. 2016

LINK

Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival

Couvrat-Desvergnes et al, J Clin Invest. 2015

LINK

Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation.

Salama et al, Xenotransplantation. 2015

LINK

Long-term IgG response to porcine Neu5Gc-antigens without transmission of PERV in burn patients treated with porcine skin xenografts

Scobie et al, J Immunol. 2013

LINK

To contact us, use the form or see our full contact below

Faculté de Médecine de Nantes
1 rue Gaston Veil – 44035 Nantes Cedex 1 – France
contact@xenothera.com

Xenothera is a start-up in biotechnology, specialized in immunology, infectious diseases and oncology

Investors already trusted us in 2014 and 2016 by funding the company for 4M€. We are raising an additional 10M€ in 2018 to complete the first-in-man clinical trial of our first product. Our products will offer a substantial patient benefit and address unsolved major public health issues